miRNA 933 Expression by Endothelial Cells is Increased by 27-Hydroxycholesterol and is More Prevalent in Plasma from Dementia Patients by Dias, I et al.
Journal of Alzheimer’s Disease 64 (2018) 1009–1017
DOI 10.3233/JAD-180201
IOS Press
1009
miRNA 933 Expression by Endothelial
Cells is Increased by 27-Hydroxycholesterol
and is More Prevalent in Plasma from
Dementia Patients
Irundika H.K. Diasa,b, Caroline L. Brownb, Kiran Shabira, M. Cristina Polidoric,d
and Helen R. Griffithse,∗
aAston Medical Research Institute, Aston Medical School, Aston University, Birmingham, UK
bLife and Health Sciences and Aston Research Centre for Healthy Ageing, Aston University, Birmingham, UK
cInstitute of Biochemistry and Molecular Biology I, Heinrich-Heine-University, Dusseldorf, Germany
dAgeing Clinical Research, Department Medicine II, University Hospital of Cologne, Cologne, Germany
eFaculty of Health and Medical Sciences, University of Surrey, Stag Hill, Guildford, UK
Handling Associate Editor: Patrizia Mecocci
Accepted 20 May 2018
Abstract. Alzheimer’s disease (AD) etiology is complex; gene and environmental risk factors may interact to predispose to
disease. From single nucleotide polymorphism analyses and genome-wide association studies, a number of candidate risk
genes for the onset of AD have been identified and cluster around lipid metabolism and inflammation. We hypothesized
that endothelial cells which line the blood-brain barrier are likely to be critical mediators of systemic metabolism within the
brain. Therefore, we have studied the effect of 27 hydroxycholesterol (27-OHC) on microvascular endothelial cell (HMVEC)
redox state, inflammatory cytokine secretion, and microRNA (miR) expression. Using a transwell method, we have studied
directional secretion profiles for the proinflammatory cytokines TNF and IL-6 and confirmed that 27-OHC induces discrete
and directional inflammatory molecular signatures from HMVEC. The lipids caused depletion of cellular glutathione and
cytokine secretion is HMVEC-redox state-dependent. Discovery miR expression change in HMVEC with and without 27-
OHC treatment was undertaken. We selected three genes for further analysis by qPCR; miR-144 and 146 expression, which
are anti-inflammatory and redox regulating modulators, were not affected significantly by 27-OHC. However, increased
expression of a putative neurotrophic regulatory factor miR933 in HMVEC with 27-OHC was confirmed by qPCR. In plasma
from patients with dementia, all three miR were found at significantly elevated levels compared to healthy older adults. These
data highlight that 27-OHC has an important regulatory effect on endothelial microvascular cells to increase expression of a
miR (–933) and secretion of inflammatory cytokines that are elevated in plasma from dementia patients.
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INTRODUCTION
A number of comorbidities have been associated
with increased risk of developing Alzheimer’s dis-
ease (AD) including metabolic syndrome, obesity,
type 2 diabetes, and chronic inflammatory disease
[1]. In partial support of the theory that inflammation
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plays a significant role in AD, some but not all
observational studies have suggested that an inverse
association exists between use of non-steroidal anti-
inflammatory drug (NSAID) use and the risk of AD
[2–6]. Similarly, evidence from observational stud-
ies has grown for an association between elevated
cholesterol, the ApoE4 allele, and AD [7].
Metabolic and hyperlipidemic conditions exert
oxidative and inflammatory stress on endothelial
cells that line blood vessels. Under stress condi-
tions, progenitor endothelial cells shed microvesicles
which are loaded with paracrine signals including
microRNA (miR). miR have emerged as critical
regulators of gene expression acting at the post-
transcriptional level to either promote degeneration or
inhibit translation of target mRNA [8]. A number of
studies have investigated miR in postmortem brains
from AD patients [9, 10]. miR are also found in extra-
cellular fluids where they may exert paracrine effects
on neighboring cells. There are several potential
explanations for their presence in plasma including
apoptosis, shedding of extracellular vesicles (EVs)
and active export by the Argonaute family from
inflammatory and vascular cells [11].
“NeurimmR”, a class of miR regulating both neu-
ronal and immune functions, have been described
[12]. Within this class, plasma miR-132 and miR-134
families have been reported as biomarkers of mild
cognitive impairment [13].
The blood-brain barrier (BBB) segregates periph-
eral from central lipid metabolism in health. BBB
dysfunction is associated with the accumulation of
several vasculotoxic and neurotoxic molecules within
the brain parenchyma, a reduction in cerebral blood
flow, and hypoxia. Endothelial cells are a major
source of plasma miR in systemic vascular disease.
Increased shedding of EVs containing miR-132 and
134 family members has been described in hyperc-
holesterolemia [13]. Our understanding of roles for
these molecules in crosstalk from the body to the
brain is still in its infancy; they may be mediators
of signaling across the BBB in AD.
Hypercholesterolemia is associated with BBB
damage, leakage and inflammation in the cortex
of animals [14]. Together, these vascular-derived
insults have been suggested to initiate and/or con-
tribute to neuronal degeneration [15]. One class
of lipid molecules with neurotoxic properties are
the hydroxycholesterols [16]. 27-hydroxycholesterol
(27-OHC), which is produced systemically, is pro-
oxidant and increases production of amyloid- (A)
by neuronal cells in culture [17].
We have previously shown that the lipid fraction of
LDL is responsible for microvascular endothelial cell
barrier leakage due to disruption of tight junctions,
can increase secretion of inflammatory mediators
such as TNF- and that in vitro-oxidized LDL is more
inflammatory toward endothelial cells than native
LDL [18]. Moreover, lipids extracted from the LDL
of patients with AD or hypercholesterolemia are more
inflammatory to microvascular endothelial cells than
lipids from the LDL of healthy subjects [18].
We and others have described an increase in
systemic oxidized lipids in patients with AD and
AD with vascular complications [18–21]. Whether
oxidized lipids can modulate endothelial cell miR
expression remains unknown. Therefore, the objec-
tives of this study are to explore the sensitivity of miR
expression by microvascular endothelial cells to the
cholesterol oxidation product 27-OHC in vitro and
relate this to miR expression in plasma from elderly
people with and without AD. Our aim is to iden-
tify specific oxysterol-sensitive circulating miR with
relevance for AD at the BBB.
MATERIALS AND METHODS
Microvascular endothelial model
Human microvascular endothelial cells (HMVEC)
were maintained as previously described [18], then
seeded (3 × 105/ml) onto 24-well polycarbonate
inserts and cultured for 7 days. 27-OHC (0–25M)
was added to the apical surface of the endothelial
barrier for 24 h.
Cell viability
Cell viability was measured using the Cell Titer-
Blue® (Promega, UK) viability assay. Transwells
with cultured cells were incubated with 100l of
1:10 diluted Cell Titer-Blue® reagent for 4 h, super-
natants from Transwell® inserts were removed to a 96
well plate, and the fluorescence was measured after
excitation at 560 nm and emission at 590 nm using
a Spectra Max Gemini XS fluorimeter (Molecular
Devices, UK).
Reduced glutathione (GSH) analysis and
cytokine secretion
HMVEC reduced GSH levels were measured by
GSH-Glo assay® (Promega, UK). Following the
cell treatments with lipids, cell culture media was
collected and cells were pelleted by centrifugation
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Table 1
Demographics of healthy control and patients with AD or AD plus
Control (n = 10) AD (n = 10) AD-Plus (n = 10) p
Age (y) 75 ± 2.7 81.2 ± 2.5 79.3 ± 1.5 NS
BMI Kg/m2 23.8 ± 0.32 23.9 ± 0.62 26.1 ± 0.31 p < 0.05
Control versus AD-plus
% of ApoE4 carriers 10% 33% 33%
Cognitive function scores 29.5 ± 0.2 20.2 ± 2.0 19.8 ± 2.3 p < 0.0001
(MMSE and clock test) 16 ± 0.4 7.0 ± 1.5 7.2 ± 1.3 Compared to control
(200 g, 10 min). Cell free media containing secreted
cytokines was stored at –20◦C until analysis for inter-
leukin (IL)-6 and tumor necrosis factor (TNF) by
ELISA (Peprotech, UK).
Barrier permeability
Change in endothelial barrier permeability post 27-
OHC treatment was analyzed by addition of 200l
of 1 mg/ml FITC-dextran apically for 24 h. The baso-
lateral and apical media was collected, the apical
surface washed twice, then the washes were com-
bined with the apical media collected. Fluorescence
of the media was read at the following wavelengths;
excitation 488 nm and emission wavelength 520 nm
using a Spectra Max Gemini XS fluorimeter (Molec-
ular Devices). The percentage fluorescence in the
basolateral compartment was calculated as a measure
of cell permeability.
miR isolation
Endothelial cells were harvested and washed in
PBS, then the cell pellet was lysed in 700l of
Trizol reagent, vortexed and centrifuged at 10,000
g for 10 min at 4◦C. The supernatants were care-
fully transferred to fresh, RNase free Eppendorfs
and stored at –80◦C until extraction. For extraction,
140l of chloroform was added, the tube sealed and
shaken vigorously for approximately 30 s. The mix-
ture was centrifuged at 12,000× g 4◦C for 15 min in
order to separate the mixture into an upper aqueous
phase and a lower organic phase. The upper aque-
ous phase was collected (approximately 350l) and
mixed with 1.5 × volume of 100% ethanol (approxi-
mately 525l) by pipetting.
Clinical populations
Healthy subjects (n = 10) and patients with demen-
tia, with and without vascular complications (n = 10
in each group) were recruited from the Unit
of Cognitive Frailty, Neurology Outpatient Clinic,
Cologne, Germany. Diagnosis of AD was by using
NINCDS–ADRDA criteria either in the presence
of vascular comorbidities and risk factors (elevated
intima-media thickness of the common carotid artery
and/or type 2 diabetes mellitus) (AD-Plus group) or
without cardiovascular comorbidities and risk fac-
tors (AD group) (Table 1) [22]. Informed consent
was obtained from the patients or their care givers
according to severity of disease and the study was
approved by the local ethics committee. All proce-
dures on human subjects were done in accord with the
Helsinki Declaration of 1975. A single blood sample
was taken and plasma was prepared by centrifugation
(200 g, 30 min).
For extraction of miR, following the manufac-
turer’s instructions, 1 ml of Qiazol lysis reagent was
added to plasma samples (200l) which were then
vortexed and incubated for 5 min at room tempera-
ture. All plasma samples were spiked with an internal
standard (1.6 × 108 copies/l of C.elegans miR-39).
Chloroform (200l) was added, then samples were
vortexed and incubated for 3 min at room temper-
ature. The samples were centrifuged for 15 min at
12000× g at 4◦C. The upper aqueous phase was col-
lected from each sample into a new collection tube
and 900l of 100% ethanol was added.
miRNA extraction from plasma
For miRNA extraction, the miRNeasy
serum/plasma kit (Qiagen; Skelton House, Lloyd
Street North, Manchester M15 6SH) was used.
The samples were added to RNeasy MinElute spin
columns and centrifuged for 15 s at 8000× g. After
washing the spin columns with RWT buffer once fol-
lowed by twice with Buffer RPE and once with 80%
ethanol. RNase-free water (14l) was added to elute
the RNA and columns were centrifuged for 1 min at
full speed. miRNA concentration was determined by
NanoDrop™ (Thermofisher Scientific, UK).
Microarray and GeneSpring® analysis
miRNA quantity was validated using an
Agilent® 2100 Bioanalyzer™ instrument (Agilent
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Technologies LDA UK Ltd, Stockport, UK) at
the University of Birmingham. A single discovery
microarray experiment was performed using miR
extracted from endothelial cells after oxidized lipid
treatment in duplicate according with the manufac-
turer’s instructions. Fluorescent array images were
collected using Agilent DNA microarray scanner
and microarray data was analyzed using GeneSpring
GX software (Agilent Technologies LDA UK Ltd,
Stockport, UK). Shift to 75.0 percentile was used as
normalization and median of all samples was applied
as baseline transformation. Up- and downregulated
genes were explored versus an experimental control
and we searched for genes that were increased or
decreased more than ten-fold for further study.
The results obtained were then analyzed using the
comparative CT method and the miRNA levels were
normalized to miRNA-16.
miRNA qPCR
miRNA samples (2 ng/l) were reverse tran-
scribed using the TaqMan® microRNA reverse
transcription kit (Applied Biosystems; Birchwood
Boulevard, Warrington, Cheshire, WA3 7QH). Fol-
lowing manufacturer’s instructions, a master mix
was prepared containing 100 mM dNTPs, reverse
transcriptase, 10× RT buffer, RNase inhibitor and
RNase-free water. The master mix and the Taq-
Man miRNA 16 (cell extracts only), 933, 144, and
146 5× primer (Applied Biosystems) were added
to the miRNA samples and thermocycler conditions
included: 30 min at 16◦C, 30 min at 42◦C, and 5 min
at 85◦C with a final hold at 4◦C.
PrecisionPLUS 2× qPCR MasterMix (Primerde-
sign Ltd; York House School Lane, Chandler’s Ford,
Eastleigh SO53 4DG) and Taqman miRNA 16, 933,
144, and 146a 20× primers (Applied Biosystems)
were used for PCR and expression levels were deter-
mined using the Stratagene Mx3000P. miR16 was
used as the housekeeper gene. Thermal cycling con-
ditions; 10 min at 95◦C, 15 s at 95◦C and 1 min at
60◦C (40 cycles), 15 s at 95◦C and 1 min at 60◦C and
15 s at 95◦C.
Using a spike in control miR from C. elegans
(mir-39) to calibrate the efficiency of miR extraction
from three plasma samples for each subject group,
we showed that recovery was 91%, 89%, and 94%
for control, AD and AD plus groups respectively and
there was no significant interaction between disease
and ability to extract miR.
Statistical analysis
Statistical significance was tested by using
ANOVA with Tukey’s post-test, student’s T test or
Mann-Whitney U test for non-parametric data using
Prism 6 (Graphpad).
RESULTS
27-OHC induces oxidative and inﬂammatory
stress in HMVEC
HMVEC were cultured on Transwells until day
7 when a tight barrier was formed as described
previously [18]. HMVEC monolayers were subse-
quently exposed to 2.5, 5, or 10M 27-OHC for
up to 24 h. FITC dextran permeability was signif-
icantly increased (Fig. 1A) but cell viability was
not changed (Fig. 1B) after 24 h incubation with up
to 25M 27-OHC. To understand whether oxida-
tive stress was induced by 27-OHC, we examined
intracellular reduced GSH in HMVEC after 2 h and
24 h of oxysterol exposure. 27-OHC (>2.5M) sig-
nificantly depleted cellular GSH concentration at
2 h and this was restored to control concentrations
after 24 h (Fig. 1C). There was no corresponding
increase in GSSG under these conditions (data not
shown). The loss of GSH at 2 h could be prevented
by co-incubation with 3 mM NAC. After 24 h expo-
sure to 27-OHC, a significant increase in both apical
and basolateral secretion of TNF- and IL-6 was
observed (Fig. 1D, E). These effects were mitigated
by co-incubation with 3 mM N-acetyl cysteine, a
precursor for glutathione synthesis. At lower con-
centrations of 27-OHC, basolateral secretion was
affected most and TNF- secretion was more sen-
sitive to 27-OHC (5M; p < 0.01) than IL-6.
27-OHC induces miR-933 expression in HMVEC
Using a single microarray discovery experiment,
we observed the presence of miR-933 versus an
absence in the experimental control, with a p < 0.05
and a two-fold higher expression. We selected miR-
933 for validation using qRT-PCR. A summary of
predicted target genes listed in Table 2 suggests
that BDNF is the top target gene for miR-933.
In addition, we studied two other miR (miR 144
and miR 146) that are expressed by endothelial
cells and are reported to be sensitive to oxidative
stress (Fig. 2). miR-933 was observed at very low
concentrations in untreated endothelial cells (Ct val-
I.H.K. Dias et al. / miR933 is Increased in Dementia and by 27-OHC 1013
Fig. 1. The effect of 27-OHC on endothelial barrier permeability. HMVEC cells were seeded in Transwell inserts for 2 weeks before treating
27-OHC at 2.5, 5 or 10M for further 24 h with or without 3mM NAC. Barrier integrity (A), viability (B), Intracellular GSH (C; at 2 and
24 h) and secreted TNF- and IL-6 levels (D and E) were measured. ∗∗p < 0.01, ∗∗∗p < 0.001, n = 3.
Table 2
Putative targets for miR933 from TargetScan database
Target gene Gene name
BDNF brain-derived neurotrophic factor
COL12A1 collagen, type XII, alpha 1
RAP2B RAP2B, member of RAS oncogene family
KCMF1 potassium channel modulatory factor 1
KPNA1 karyopherin alpha 1 (importin alpha 5)
DAB2IP DAB2 interacting protein
PEA15 phosphoprotein enriched in astrocytes 15
ues >30); however, 25M 27-OHC elicited more
than 100-fold increase in expression of miR-933. miR
144 expression remained unchanged after 24 h expo-
sure to 27-OHC (1–25M). The expression of miR
146a was increased up to three-fold at the highest con-
centration of 27-OHC tested (25M) (Fig. 2C). Low
concentrations of 27-OHC (<10M) had no effect
on expression of any of the miR studied.
27-OHC and miR in plasma from patients with
dementia
To explore whether miR-933 secretion into the
circulation was more prevalent in dementia, we
examined the plasma from patients with and with-
out AD and vascular dementia. The demographics
of the cohorts is shown in Table 1. ApoE4 allele
frequency was greater in dementia patients (Table 1).
Cognitive function of patients with AD with vascu-
lar co-morbidities, AD and healthy control subjects
were determined by combination of two well-known
cognitive screening brief tests; Mini-Mental Status
Examination (MMSE) and clock drawing test. The
comparison of the cognitive scores by non-parametric
Mann-Whitney analysis shows that both AD plus and
AD groups have significant (p < 0.0001) cognitive
deficits compared to healthy controls.
To explore whether plasma from patients with
dementia have increased levels of circulating miR-
933, total miR was extracted from the plasma of
each patient individually from the three groups, AD,
AD-Plus, and control subjects. In common with pre-
vious studies, miR 144 and 146a were elevated in
plasma from dementia subjects by approximately two
orders of magnitude (Fig. 3). In contrast, miR933
was scarcely detectable in healthy subjects (Ct > 35)
and was found at ten times the order of magnitude
in plasma from dementia patients (Fig. 3). AD-plus
patients tended to higher levels of circulating miR
than AD patients.
By way of further analysis, we explored whether
there was any relationship between cognitive func-
tion and plasma miR933. On the population of 30
subjects examined, there was no significant asso-
ciation between MMSE score and plasma miR
933 (Fig. 4).
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Fig. 2. Expression of miR 144, miR 146a, and miR 933 in response to 27-OHC. HMVEC cells (1 × 106) were treated with 10M or 25M
27-OHC for 24 h. Total micro RNA was extracted as described. miR levels were quantified by qRT-PCR relative to miR16. ∗p < 0.05, n = 3.
Fig. 3. Expression of miR 144, miR 146a, and miR 933 in plasma from older adults. miRNA was extracted using the miRNeasy kit and miR
quantitated by qPCR for 10 subjects in each group. The demographic profile of subjects is shown in Table 1.
Fig. 4. Stratification of miR 933 according to cognitive impairment
represented by MMSE scores.
DISCUSSION
Previously we have shown that LDL and its lipids
can increase the permeability of a HMVEC bar-
rier and have suggested that endothelial cells which
line the BBB are likely to be critical mediators
of systemic metabolic effects within the brain [16,
18]. We have expanded these studies to examine a
specific oxysterol, 27-OHC, which is found at
different concentrations in AD patient plasma, cere-
brospinal fluid, and brains and has neurotoxic
properties [17]. Here we identified for the first time
that miR-933 expression is increased in HMVEC
by 27-OHC. Others have suggested that miR-933
can interfere with nerve growth factor translation
[23] and might therefore be play a role to inhibit
BDNF secretion. Using a HMVEC model, we have
confirmed that 27-OHC releases discrete inflam-
matory molecular signatures, comprising of TNF
and IL-6, preferentially into the “brain” compart-
ment; this effect is endothelial redox state-dependent.
Cytokine-producing endothelial cells also secrete
large quantities of EVs [24]. EVs are known to
be important cargo vehicles for releasing active
molecules, e.g., miR and lipids to distant sites [25].
EVs generated by epithelial cells in the choroid
plexus have been observed within the cerebrospinal
fluid, supporting the BBB as a point of entry of sys-
temic EVs into the brain [26].
Neuronal EVs are observed with higher concentra-
tions of amyloid and tau in plasma from patients with
dementia [27]. Here we have shown that AD patients
with vascular complications have higher circulating
concentrations of miR-933, miR-146a, and miR-144
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than control subjects. We have not explored whether
these miR are free or are within EVs. Our report is
the first to identify elevated circulating levels of miR-
933 in dementia. With enhanced permeability and the
potential for directional secretion from endothelial
cells into the brain, miR-933 may act as a paracrine
inhibitor of neuronal BDNF expression.
Several studies have explored miR144 in relation
to dementia; it is regulated by the redox sensitive
transcription factor AP1 and it has been shown to
inhibit expression of ADAMT-10, which in turn is an
inhibitor of A production [28–30]. An increase in
miR144 increases A production in neuronal cells.
miR146a, an inhibitor of innate immune signaling,
is induced by NF-kB and activates a negative feed-
back loop inhibiting inflammatory responses [31].
Reduced expression of miR-146a links subclinical
inflammation and insulin resistance in type 2 dia-
betes mellitus. Paradoxically, we show that miR-146a
is increased in people with dementia and increased
expression of miRNA-146a has been reported in AD
transgenic mouse models [32]. miRNA 146a is also
increased in brain during systemic inflammation [26].
This may represent an adaptive response that aims to
limit inflammation. The increased expression of miR-
144 and 146a in plasma from patients with dementia
may be a consequence of EV secretion from a range
of different cells beyond endothelial cells including
inflammatory cells such as monocytes.
Histological studies have shown increased inflam-
matory cyclooxygenase expression, oxidative stress,
and more oxidized lipid deposition in the postmortem
brain [33, 34]. The widespread epidemiological
association between insulin resistance, obesity, and
subclinical inflammation with the loss of cognitive
function has been further substantiated recently by
changes in the metabolic regulatory miR-29a, miR-
335, and miR-125b in the brain [35]. However, most
of these studies, including ours has only focused
on individual miRNAs, and the sample sizes are
too low to conclude diagnostic potential. Therefore,
extensive and genome-wide analyses of the miR-
NAs in the circulating blood of dementia patients
are still needed in large-sample studies for disease
stratification.
Vascular risk factors appear to influence the future
risk of dementia, in particular vascular and mixed-
type AD [36] but no clear effects of lipid-lowering
or anti-inflammatory interventions are evident in
patients with established disease. In a recent study,
we have observed that 27-OHC is not modulated by
statin intervention in people. This is consistent with
an enzymatic synthetic pathway rather than auto-
oxidation of cholesterol, hence lipid lowering drugs
would not be likely to ameliorate any elevation in
27-OHC seen in dementia [37]. In the present study,
we show that after treatment with 27-OHC, there is
an associated switch the regulatory miR profile in
endothelial cells towards modulating inflammation
and inhibiting trophic factor expression.
Here we have investigated 27-OHC as a putative
mediator of systemic metabolic effects into the brain
compartment in an in vitro microvascular endothelial
model. Using this approach, we identified both neu-
romodulatory and inflammatory effects of 27-OHC.
We have identified a previously unrecognized tar-
get miR as a possible anti-neurotrophic factor and
this has led us to investigate and identify the same
miR at elevated concentrations in dementia patients.
It is beyond the scope of this study to investigate the
cause of miR933 upregulation in vivo. In considering
whether oxysterols such as 27-OHC may exert any
pathophysiologic effect in vivo, e.g., on miR-933,
it is important to be cognizant of the low concen-
trations of oxysterols (∼5M) found in vivo, their
potential to bind to oxysterol binding proteins and
therefore transient nature. miR-933 represents a spe-
cific oxysterol-sensitive circulating miR that is found
at elevated levels in dementia patient plasma.
Our data highlight that 27-OHC has an impor-
tant regulatory effect on endothelial microvascular
cells and can increase expression of miR-933.
Redox-dependent directional secretion of inflamma-
tory cytokines and alterations in neurotrophic factor
regulatory miR expression are induced in endothe-
lial cells by 27-OHC in a pattern that is consistent
with neurotoxic and inflammatory stress. A miRBase
scan revealed that miR-933 may target BDNF and
therefore anti-miR933 may be usefully explored for
neuroprotective properties, for example in prodromal
disease models.
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